Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplash
Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic demand and positive global healthcare trends. Analysts see long-term growth potential from aging populations and innovation. Emerging opportunities from supply chain diversification away from China also present a positive outlook for Indian pharmaceutical companies.
Further consolidation ahead for Nifty? Here's today's outlook and top picks
Ajit Mishra of Religare Broking has recommended buying the shares of Fortis Healthcare, RBL Bank, and Eternal today
Margin play: Why Supertails is doubling down on the lucrative pet healthcare market
With medical services yielding double the margins of retail, the startup is expanding its clinic and pharmacy footprint to anchor itself at the centre of India's formalizing pet economy.
Indian cancer patients battle shortage of key drugs as platinum costs surge
Cancer patients in India are struggling to find essential platinum-based drugs. A surge in global platinum prices and supply chain issues are causing shortages. This forces patients to search extensively for medication. Some drugmakers have reduced production. The situation puts immense pressure on the healthcare system and patients seeking treatment.
Manipal Health picks up hospital building in Bengaluru through 30-year lease
Manipal Health Enterprises has secured a large hospital building in Bengaluru's Yelahanka area. The lease spans nearly 30 years, with total rental payments projected at over Rs 816 crore. This move signifies the hospital chain's ongoing expansion across major Indian cities. The transaction underscores the growing trend of healthcare operators prioritizing long-term occupancy in prime urban markets.
BofA sees domestic growth, Semaglutide opportunity driving pharma in FY27
Neha Manpuria, Senior Analyst - Pharma, Healthcare at BofA Global Research, says semaglutide launches could emerge as a key growth driver for Indian pharma companies in FY27.
Entero Healthcare Gets Target Price Hike On Strong Q4 Earnings As Jefferies Eyes 17% Upside
Jefferies said Entero's medtech segment is expected to cross Rs 10 billion in FY27 as the business has better margins
Blue Jet Healthcare gains 8% post Q4; analysts split on near-term prospects
Emkay Global has retained its 'Reduce' rating, while Motilal Oswal has maintained its 'Buy' stance, reflecting contrasting expectations on recovery in key business segments and the margin trajectory
Healthcare, engineering and specialty chemicals remain key market themes: Mayuresh Joshi
Mayuresh Joshi, Director Research at Marketsmith India, believes execution will remain key for companies like Suzlon, while healthcare, engineering and select speciality chemical names continue to offer strong growth opportunities. He also sees India-focused engineering and capital goods companies remaining resilient despite global uncertainties. Joshi says investors should stay selective in IT, remains positive on Navin Fluorine, and is closely tracking niche AI-linked opportunities emerging in smaller tech firms.
Sakar Healthcare partners with Zydus Lifesciences for GCC Markets
Sakar Healthcare has partnered with Zydus Lifesciences to supply oncology products in GCC countries and other emerging markets. This marks the company's 40th global agreement in the anti-cancer segment. Sakar Healthcare is expanding its international oncology business and strengthening its presence in emerging markets. The company is also progressing with regulatory filings and approvals in highly regulated markets.
Engineers India Ltd leads losers in 'A' group
Ganesha Ecosphere Ltd, Central Bank of India, Max Healthcare Institute Ltd and GMR Power & Urban Infra Ltd are among the other losers in the BSE's 'A' group today, 22 May 2026.
Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sector
Bernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future growth for the Indian healthcare sector. Key drivers include AI-led innovation, incremental advancements in niche areas, and improved quality culture. Attractive valuations also support this positive outlook for the industry.